1,200 reports of this reaction
2.4% of all HALOPERIDOL reports
#6 most reported adverse reaction
EXTRAPYRAMIDAL DISORDER is the #6 most commonly reported adverse reaction for HALOPERIDOL, manufactured by Advagen Pharma Ltd. There are 1,200 FDA adverse event reports linking HALOPERIDOL to EXTRAPYRAMIDAL DISORDER. This represents approximately 2.4% of all 49,192 adverse event reports for this drug.
Patients taking HALOPERIDOL who experience extrapyramidal disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXTRAPYRAMIDAL DISORDER is a less commonly reported adverse event for HALOPERIDOL, but still significant enough to appear in the safety profile.
In addition to extrapyramidal disorder, the following adverse reactions have been reported for HALOPERIDOL:
The following drugs have also been linked to extrapyramidal disorder in FDA adverse event reports:
EXTRAPYRAMIDAL DISORDER has been reported as an adverse event in 1,200 FDA reports for HALOPERIDOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXTRAPYRAMIDAL DISORDER accounts for approximately 2.4% of all adverse event reports for HALOPERIDOL, making it a notable side effect.
If you experience extrapyramidal disorder while taking HALOPERIDOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.